Subscribe
Menu Icon
Refresh Miami Logo
Search Icon
Sign Up Sign In

Neurolief raises $6M to fuel U.S. rollout of at-home depression therapy

Nancy Dahlberg
Nancy Dahlberg
PinLinkedIn

In a significant move aiming to bridge the gap in mental health accessibility, Neurolief, a Coral Springs-based medical technology company,  announced today that it has secured a $6 million investment.

 Neurolief recently received  FDA premarket approval of Proliv Rx, its brain neuromodulation system designed for patients who have seen little to no success with traditional antidepressants. The investment marks a pivotal moment for the medical technology sector, as it accelerates the commercial scale-up what the company says is the first and only FDA-approved, at-home prescription therapy for adults with Major Depressive Disorder who have failed at least one medication trial.

For millions of Americans, the journey to finding relief from depression is often stalled by “treatment-resistant” symptoms. While clinical neuromodulation, such as Deep Transcranial Magnetic Stimulation, or Deep TMS, has proven effective, many patients face logistical hurdles, including the need for daily travel to specialized clinics and lengthy referral wait times.

Proliv Rx aims to dismantle these barriers. Though the therapy is prescribed and supervised by a physician, it is self-administered by the patient at home. This hybrid model maintains clinical rigor while providing the convenience necessary for real-world adoption.

Stay ahead of Miami Tech

Join 16,000+ founders, investors, and tech professionals.

Check your inbox for a confirmation email.

Proliv Rx was developed to close a critical access gap at a pivotal point in the depression care journey, said Scott Drees, CEO of Neurolief. ” With FDA approval and early commercial traction, we are scaling a model that delivers rigorous, evidence-based care in a way that is accessible and built for real-world adoption.”

The milestone-based $6 million injection is from BrainsWay Ltd, a medtech company based in Israel and a leader in noninvasive neurostimulation. The funding will accelerate the U.S. rollout of Proliv Rx, expanding the reach of neuromodulation beyond the confines of the clinic. “As health systems shift toward value-based care, reaching high-need depression patients faster and more effectively is becoming increasingly critical,” said Neurolief Chief Medical Officer Dr. Owen Muir.

In South Florida, medical technology companies that raised capital in 2025 made up the second largest sector of fundings, behind fintech. According the 2025 eMerge Insights report released today, 56 medtech companies raised a total of $821 million last year. But this year is off to a swift start with over $600 million in medtech funding already logged in Q1.

READ MORE IN REFRESH MIAMI:

Nancy Dahlberg
Latest posts by Nancy Dahlberg (see all)